Liver Fibrosis in Nonalcoholic Steatohepatitis
When chronic inflammation occurs in the liver due to viral infection, excessive drinking alcohol, fat accumulation, and abnormal immune challenge, the ECM is excessively deposited. This causes structural changes in the liver and a decrease in the number of hepatocytes, which in turn leads to loss of liver function or liver cancer.
Viral infection or alcoholic hepatitis has a clear cause, so many treatments have been developed so far. In contrast, nonalcoholic steatohepatitis (NASH), which is caused by various chronic diseases, has a complicated treatment mechanism, so there is no approved treatment until now, and it is dependent only on surgical operation by liver transplantation.
As the number of patients requiring transplantation is significantly higher than that of liver donors, the prevalence and number of NASH patients are steadily increasing.
In order to treat liver fibrosis, it is necessary to control inflammation of the liver tissue and to regenerate the tissue in which fibrosis has occurred. Intencell® is expected to work effectively in the treatment of liver fibrosis by modulating the differentiation of macrophages and dissolving the excessively secreted extracellular matrix.